Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Uno studio per valutare l'efficacia, la sicurezza, la farmacocinetica e la farmacodinamica dell'emicizumab sottocutaneo nei partecipanti dalla nascita ai 12 mesi di età con emofilia A senza inibitori (HAVEN 7)

30 settembre 2026 aggiornato da: Hoffmann-La Roche

Uno studio di fase IIIb, multicentrico, in aperto, a braccio singolo per valutare l'efficacia, la sicurezza, la farmacocinetica e la farmacodinamica dell'emicizumab sottocutaneo in pazienti dalla nascita ai 12 mesi di età con emofilia A senza inibitori

This is a Phase IIIb, multicenter, open-label, single-arm study of prophylactic emicizumab in previously untreated and minimally treated patients at study enrollment from birth to ≤12 months of age with severe hemophilia A (intrinsic factor VIII [FVIII] level <1%) without FVIII inhibitors. The study is designed to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of emicizumab administered at 3 milligrams per kilogram of body weight (mg/kg) once every 2 weeks (Q2W) for 52 weeks. After 1 year of treatment, participants will continue to receive emicizumab (1.5 mg/kg once every week [QW], 3 mg/kg Q2W or 6 mg/kg once every 4 weeks [Q4W]) over a 7-year long-term follow-up period under this study frame.

Panoramica dello studio

Stato

Attivo, non reclutante

Condizioni

Intervento / Trattamento

Tipo di studio

Interventistico

Iscrizione (Effettivo)

55

Fase

  • Fase 3

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

    • New South Wales
      • Westmead, New South Wales, Australia, 2145
        • The Children's Hospital at Westmead
    • Victoria
      • Parkville, Victoria, Australia, 3052
        • Royal Children's Hospital
    • Western Australia
      • Nedlands, Western Australia, Australia, 6009
        • Perth Children's Hospital
      • Vienna, Austria, 1090
        • Medizinische Universität Wien
      • Brussels, Belgio, 1200
        • Cliniques Universitaires St-Luc
      • Leuven, Belgio, 3000
        • UZ Leuven Gasthuisberg
    • São Paulo
      • Ribeirão Preto, São Paulo, Brasile, 14051-140
        • Hospital das Clínicas Faculdades Médicas de Ribeirão Preto
    • Ontario
      • Ottawa, Ontario, Canada, K1H 8L1
        • Children's Hospital of Eastern Ontario
      • Toronto, Ontario, Canada, M5G 1X8
        • The Hospital for Sick Children
      • Paris, Francia, 75015
        • Groupe Hospitalier Necker Enfants Malades
      • Bonn, Germania, 53127
        • Universitätsklinikum Bonn
      • Mörfelden-Walldorf, Germania, 64546
        • Hämophilie-Zentrum Rhein Main GmbH
      • Tel HaShomer, Israele, 5262100
        • Sheba Medical Center - National Hemophilia Center
    • Campania
      • Naples, Campania, Italia, 80123
        • AORN Santobono Pausilipon
    • Emilia-Romagna
      • Parma, Emilia-Romagna, Italia, 43126
        • AOU di Parma
    • Lombardy
      • Milan, Lombardy, Italia, 20122
        • IRCCS Ca' Granda Ospedale Maggiore Policlinico
    • Tuscany
      • Florence, Tuscany, Italia, 50134
        • AOU Careggi
      • Glasgow, Regno Unito, G51 4TF
        • Queen Elizabeth University Hospital
      • Madrid, Spagna, 28046
        • Hospital Universitario la Paz
      • Seville, Spagna, 41013
        • Hospital Universitario Virgen del Rocio
    • Barcelona
      • Esplugues de Llobregat, Barcelona, Spagna, 08950
        • Hospital Sant Joan de Deu
    • Arizona
      • Phoenix, Arizona, Stati Uniti, 85016
        • Phoenix Children's Hospital
    • California
      • Los Angeles, California, Stati Uniti, 90027
        • Children's Hospital Los Angeles
    • Colorado
      • Aurora, Colorado, Stati Uniti, 80045
        • University of Colorado Denver, Children's Hospital
    • Louisiana
      • New Orleans, Louisiana, Stati Uniti, 70112
        • Tulane University Health Sciences Center
    • Michigan
      • Ann Arbor, Michigan, Stati Uniti, 48109-0934
        • University of Michigan
    • Washington
      • Seattle, Washington, Stati Uniti, 98105
        • Seattle Children's Hospital
      • Johannesburg, Sud Africa, 2193
        • Charlotte Maxeke Johannesburg Hospital
      • Adana, Turchia (Türkiye), 01130
        • Adana Acibadem Hospital
      • Ankara, Turchia (Türkiye), 06100
        • Hacettepe University Medical Faculty
      • Izmir, Turchia (Türkiye), 35100
        • Ege University, School of Medicine
      • Samsun, Turchia (Türkiye), 55139
        • Ondokuz Mayis Univ. Med. Fac.

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 1 secondo a 1 anno (Bambino)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • Age from birth to ≤12 months at time of informed consent
  • Body weight ≥3 kilograms (kg) at time of informed consent. Patients with a lower body weight can be enrolled after they have reached a body weight of 3 kg. Premature babies (gestational age <38 weeks) may be enrolled as long as they have reached a body weight of 3 kg. For premature babies, the corrected gestational age should be reported.
  • Mandatory receipt of vitamin K prophylaxis according to local standard practice
  • Diagnosis of severe congenital hemophilia A (intrinsic FVIII level <1%)
  • A negative test for FVIII inhibitor (i.e., <0.6 Bethesda units [BU]/mL) locally assessed during the 2-week screening period
  • No history of documented FVIII inhibitor (i.e., <0.6 BU/mL), FVIII drug-elimination half-life <6 hours, or FVIII recovery <66%
  • Previously untreated patients or minimally treated patients (i.e., up to 5 days of exposure with hemophilia-related treatments, such as plasma-derived FVIII, recombinant FVIII, fresh frozen plasma, cryoprecipitate, or whole blood products)
  • Documentation of the details of the hemophilia-related treatments received since birth
  • Documentation of the details of the bleeding episodes since birth
  • For patients from birth to <3 months of age at the time of study entry: no evidence of active intracranial hemorrhage, as confirmed by a negative cranial ultrasound at screening irrespective of delivery mode
  • Adequate hematologic, hepatic, and renal function, as defined in the protocol
  • For parents/caregivers: willingness and ability to comply with the study protocol requirements, scheduled visits, treatment plans, laboratory tests, completion of applicable questionnaires, and other study procedures

Exclusion Criteria:

  • Inherited or acquired bleeding disorder other than severe hemophilia A
  • Use of systemic immunomodulators (e.g., interferon) at enrollment or planned use during the study
  • Receipt of any of the following: Prior use of emicizumab prophylaxis including investigational or commercial emicizumab; An investigational drug to treat or reduce the risk of hemophilic bleeds within 5 drug-elimination half-lives of last drug administration; A non-hemophilia-related investigational drug within the last 30 days or 5 drug-elimination half-lives, whichever is shorter; An investigational drug concurrently
  • Current active severe bleed, such as intracranial hemorrhage
  • Planned surgery (excluding minor procedures, e.g., circumcision, CVAD placement) during the study
  • History of clinically significant hypersensitivity associated with monoclonal antibody therapies or components of the emicizumab injection
  • Patients who are at high risk for thrombotic microangiopathy (TMA) (e.g., have a previous medical or family history of TMA, such as thrombotic thrombocytopenic purpura, atypical hemolytic uremic syndrome) in the investigator's judgment
  • Previous or current treatment for thromboembolic disease (with the exception of previous catheter-associated thrombosis in patients for whom anti-thrombotic treatment is not currently ongoing) or signs of thromboembolic disease
  • Any hereditary or acquired maternal condition that may predispose the patient to thrombotic events (e.g., inherited thrombophilias antiphospholipid syndrome)
  • Other diseases (e.g., certain autoimmune diseases) that may increase risk of bleeding or thrombosis
  • Known infection with HIV, hepatitis B virus, or hepatitis C virus
  • Serious infection requiring antibiotics or antiviral treatments within 14 days prior to screening
  • Concurrent disease, treatment, abnormality in clinical laboratory tests, vital signs measurements, or physical examination findings that could interfere with the conduct of the study or that would, in the opinion of the investigator or Sponsor, preclude the patient's safe participation in and completion of the study or interpretation of the study results
  • Unwillingness of the parent or caregiver to allow receipt of blood or blood products, or any standard-of-care treatment for a life-threatening condition
  • Any other medical, social, or other condition that may prevent adequate compliance with the study protocol in the opinion of the investigator

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: N / A
  • Modello interventistico: Assegnazione di gruppo singolo
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Emicizumab

Initially, all participants will receive 4 loading doses of 3 milligrams per kilogram (mg/kg) emicizumab subcutaneously (SC) once every week (QW) for 4 weeks followed by the maintenance dosing regimen 3 mg/kg emicizumab SC once every 2 weeks (Q2W) for a total of 52 weeks. Starting from Week 17 of treatment, individual participants may have their dose up-titrated to 3 mg/kg SC QW if they experience suboptimal bleeding control.

At the Week 53 clinic visit following consultation with the treating physician, parents/caregivers may elect for their child to continue with the maintenance 3-mg/kg SC Q2W dosing regimen or to switch to the maintenance 1.5-mg/kg SC QW or 6-mg/kg SC once every 4 weeks (Q4W) dosing regimen for the subsequent 7-year long-term follow-up period.

During the study, participants will be treated with emicizumab until unacceptable toxicity, discontinuation from the study due to any cause, or other criteria specified in the protocol, whichever occurs first.

Altri nomi:
  • Hemlibra
  • RO5534262
  • RG6013
  • ACE910

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Model-Based Annualized Bleeding Rate for Treated Bleeds
Lasso di tempo: From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)

The number of treated bleeds over the efficacy period was estimated as an annualized bleeding rate (ABR) using a negative binomial regression model, which accounts for different follow-up times. A treated bleed was defined as a bleed that was directly followed by a hemophilia medication reported to be a "treatment for bleed". The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.

From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)
Mean Calculated Annualized Bleeding Rate for Treated Bleeds
Lasso di tempo: From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)

The number of treated bleeds over the efficacy period is presented here as a calculated annualized bleeding rate (ABR) that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A treated bleed was defined as a bleed that was directly followed by a hemophilia medication reported to be a "treatment for bleed". The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.

From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)
Median Calculated Annualized Bleeding Rate for Treated Bleeds
Lasso di tempo: From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)

The number of treated bleeds over the efficacy period is presented here as a calculated annualized bleeding rate (ABR) that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A treated bleed was defined as a bleed that was directly followed by a hemophilia medication reported to be a "treatment for bleed". The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.

From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)
Model-Based Annualized Bleeding Rate for All Bleeds
Lasso di tempo: From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)

The number of all bleeds over the efficacy period was estimated as an annualized bleeding rate (ABR) using a negative binomial regression model, which accounts for different follow-up times. In this outcome measure, all bleeds are included, irrespective of treatment with coagulation factors, with the following exception: bleeds due to surgery/procedure are excluded. As "all bleeds" comprises both treated and non-treated bleeds, the 72-hour rule was implemented separately for treated and non-treated bleeds. For treated bleeds, the 72-hour rule meant that two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. For non-treated bleeds, the 72-hour rule was implemented by calculating a treatment-free period of 72 hours from the bleed itself.

From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)
Mean Calculated Annualized Bleeding Rate for All Bleeds
Lasso di tempo: From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)

The number of all bleeds over the efficacy period is presented here as a calculated annualized bleeding rate (ABR) that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. In this outcome measure, all bleeds are included, irrespective of treatment with coagulation factors, with the following exception: bleeds due to surgery/procedure are excluded. As "all bleeds" comprises both treated and non-treated bleeds, the 72-hour rule was implemented separately for treated and non-treated bleeds. For treated bleeds, the 72-hour rule meant that two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. For non-treated bleeds, the 72-hour rule was implemented by calculating a treatment-free period of 72 hours from the bleed itself.

From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)
Median Calculated Annualized Bleeding Rate for All Bleeds
Lasso di tempo: From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)

The number of all bleeds over the efficacy period is presented here as a calculated annualized bleeding rate (ABR) that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. In this outcome measure, all bleeds are included, irrespective of treatment with coagulation factors, with the following exception: bleeds due to surgery/procedure are excluded. As "all bleeds" comprises both treated and non-treated bleeds, the 72-hour rule was implemented separately for treated and non-treated bleeds. For treated bleeds, the 72-hour rule meant that two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. For non-treated bleeds, the 72-hour rule was implemented by calculating a treatment-free period of 72 hours from the bleed itself.

From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)
Model-Based Annualized Bleeding Rate for Treated Spontaneous Bleeds
Lasso di tempo: From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)

The number of treated spontaneous bleeds over the efficacy period was estimated as an annualized bleeding rate (ABR) using a negative binomial regression model, which accounts for different follow-up times. A treated spontaneous bleed was defined as a treated bleed (bleed directly followed by a hemophilia medication reported to be a "treatment for bleed") with no other known contributing factor such as trauma or procedure/surgery. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.

From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)
Mean Calculated Annualized Bleeding Rate for Treated Spontaneous Bleeds
Lasso di tempo: From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)

The number of treated spontaneous bleeds over the efficacy period is presented here as a calculated annualized bleeding rate (ABR) that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A treated spontaneous bleed was defined as a treated bleed (bleed directly followed by a hemophilia medication reported to be a "treatment for bleed") with no other known contributing factor such as trauma or procedure/surgery. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.

From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)
Median Calculated Annualized Bleeding Rate for Treated Spontaneous Bleeds
Lasso di tempo: From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)

The number of treated spontaneous bleeds over the efficacy period is presented here as a calculated annualized bleeding rate (ABR) that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A treated spontaneous bleed was defined as a treated bleed (bleed directly followed by a hemophilia medication reported to be a "treatment for bleed") with no other known contributing factor such as trauma or procedure/surgery. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.

From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)
Model-Based Annualized Bleeding Rate for Treated Joint Bleeds
Lasso di tempo: From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)

The number of treated joint bleeds over the efficacy period was estimated as an annualized bleed rate (ABR) using a negative binomial regression model, which accounts for different follow-up times. A treated joint bleed was defined as a bleed with type reported as "joint" based on at least one of the following symptoms: increasing swelling or warmth of the skin over the joint and/or increasing pain, decreased range of motion, or difficulty using the joint compared with baseline, and the bleed was directly followed by a hemophilia medication reported to be a "treatment for bleed". The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.

From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)
Mean Calculated Annualized Bleeding Rate for Treated Joint Bleeds
Lasso di tempo: From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)

The number of treated joint bleeds over the efficacy period is presented here as a calculated annualized bleed rate (ABR) that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A treated joint bleed was defined as a bleed with type reported as "joint" based on at least one of the following symptoms: increasing swelling or warmth of the skin over the joint and/or increasing pain, decreased range of motion, or difficulty using the joint compared with baseline, and the bleed was directly followed by a hemophilia medication reported to be a "treatment for bleed". The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.

From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)
Median Calculated Annualized Bleeding Rate for Treated Joint Bleeds
Lasso di tempo: From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)

The number of treated joint bleeds over the efficacy period is presented here as a calculated annualized bleed rate (ABR) that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A treated joint bleed was defined as a bleed with type reported as "joint" based on at least one of the following symptoms: increasing swelling or warmth of the skin over the joint and/or increasing pain, decreased range of motion, or difficulty using the joint compared with baseline, and the bleed was directly followed by a hemophilia medication reported to be a "treatment for bleed". The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.

From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Concentrazioni plasmatiche minime (Ctrough) di Emicizumab
Lasso di tempo: Predose alle settimane 1, 3, 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49 e 53
Predose alle settimane 1, 3, 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49 e 53
Incidenza di anticorpi anti-emicizumab
Lasso di tempo: Settimane 1, 5, 17, 29, 41 e 53, e successivamente come clinicamente indicato fino al completamento dello studio (fino a 8 anni)
Settimane 1, 5, 17, 29, 41 e 53, e successivamente come clinicamente indicato fino al completamento dello studio (fino a 8 anni)
Punteggio totale sulla salute delle articolazioni dell'emofilia (HJHS) a punti temporali specifici durante il periodo di follow-up a lungo termine
Lasso di tempo: Agli anni 4, 5, 6, 7 e 8 di follow-up
Agli anni 4, 5, 6, 7 e 8 di follow-up
Punteggio della risonanza magnetica (MRI) di articolazioni specifiche in punti temporali specifici durante il periodo di follow-up a lungo termine
Lasso di tempo: Agli anni 5 e 8 di follow-up
Agli anni 5 e 8 di follow-up
Incidenza e gravità degli eventi avversi, con gravità determinata secondo la scala di classificazione della tossicità dell'Organizzazione Mondiale della Sanità (OMS)
Lasso di tempo: Dalla prima dose di emicizumab fino al completamento dello studio (8 anni)
Dalla prima dose di emicizumab fino al completamento dello studio (8 anni)
Incidenza di eventi tromboembolici
Lasso di tempo: Dalla prima dose di emicizumab fino al completamento dello studio (8 anni)
Dalla prima dose di emicizumab fino al completamento dello studio (8 anni)
Incidenza della microangiopatia trombotica
Lasso di tempo: Dalla prima dose di emicizumab fino al completamento dello studio (8 anni)
Dalla prima dose di emicizumab fino al completamento dello studio (8 anni)
Incidenza e gravità delle reazioni nel sito di iniezione, con gravità determinata secondo la scala di classificazione della tossicità dell'OMS
Lasso di tempo: Dalla prima dose di emicizumab fino al completamento dello studio (8 anni)
Dalla prima dose di emicizumab fino al completamento dello studio (8 anni)
Incidenza di eventi di ipersensibilità grave, anafilassi ed anafilattoidi
Lasso di tempo: Dalla prima dose di emicizumab fino al completamento dello studio (8 anni)
Dalla prima dose di emicizumab fino al completamento dello studio (8 anni)
Incidenza di eventi avversi che hanno portato alla sospensione del farmaco in studio
Lasso di tempo: Dalla prima dose di emicizumab fino al completamento dello studio (8 anni)
Dalla prima dose di emicizumab fino al completamento dello studio (8 anni)
Variazione rispetto al basale della frequenza cardiaca nel tempo
Lasso di tempo: Basale, settimane 1, 2, 3, 4, 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49 e 53 e annualmente durante i 7 anni di follow-up periodo fino al completamento degli studi (fino a 8 anni)
Basale, settimane 1, 2, 3, 4, 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49 e 53 e annualmente durante i 7 anni di follow-up periodo fino al completamento degli studi (fino a 8 anni)
Variazione rispetto al basale della frequenza respiratoria nel tempo
Lasso di tempo: Basale, settimane 1, 2, 3, 4, 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49 e 53 e annualmente durante i 7 anni di follow-up periodo fino al completamento degli studi (fino a 8 anni)
Basale, settimane 1, 2, 3, 4, 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49 e 53 e annualmente durante i 7 anni di follow-up periodo fino al completamento degli studi (fino a 8 anni)
Variazione rispetto al basale della temperatura corporea nel tempo
Lasso di tempo: Basale, settimane 1, 2, 3, 4, 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49 e 53 e annualmente durante i 7 anni di follow-up periodo fino al completamento degli studi (fino a 8 anni)
Basale, settimane 1, 2, 3, 4, 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49 e 53 e annualmente durante i 7 anni di follow-up periodo fino al completamento degli studi (fino a 8 anni)
Variazione rispetto al basale della pressione arteriosa sistolica nel tempo
Lasso di tempo: Basale, settimane 1, 2, 3, 4, 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49 e 53 e annualmente durante i 7 anni di follow-up periodo fino al completamento degli studi (fino a 8 anni)
Basale, settimane 1, 2, 3, 4, 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49 e 53 e annualmente durante i 7 anni di follow-up periodo fino al completamento degli studi (fino a 8 anni)
Variazione rispetto al basale della pressione arteriosa diastolica nel tempo
Lasso di tempo: Basale, settimane 1, 2, 3, 4, 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49 e 53 e annualmente durante i 7 anni di follow-up periodo fino al completamento degli studi (fino a 8 anni)
Basale, settimane 1, 2, 3, 4, 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49 e 53 e annualmente durante i 7 anni di follow-up periodo fino al completamento degli studi (fino a 8 anni)
Number of Participants According to Hematology and Serum Chemistry Laboratory Test Result Shifts From Baseline WHO Grade to the Highest WHO Grade Post-Baseline
Lasso di tempo: Baseline, Weeks 4, 13, 21, 29, 37, 45, and 53

Laboratory parameters for hematology and blood chemistry were measured at baseline and over time, and the values were compared with a standard reference range. Values outside the standard reference range were considered laboratory abnormalities and graded according to the World Health Organization (WHO) toxicity grading scale, ranging from lowest (Grade 1) to greatest (Grade 4) deviation from standard in the direction indicated for the abnormality (i.e., below (Low) or above (High) the reference range; 'Not Low' and 'Not High' indicate values within the reference range). Participants were categorized according to their laboratory test result shift from baseline WHO grade to highest WHO grade at any point post-baseline (up to Week 53) for each parameter. 'Missing' indicates that the test result was not available.

Baseline, Weeks 4, 13, 21, 29, 37, 45, and 53
Incidence of De Novo Development of Factor VIII Inhibitors
Lasso di tempo: As clinically indicated from baseline until study completion (up to 8 years)

As per the protocol, after any 3 exposure days to FVIII or a block of FVIII exposure days (e.g., a block is defined as a minimum of two consecutive doses of FVIII) administered for treatment of a bleed, a surgical procedure, or other (e.g., preventative doses before activity), one plasma sample for anti-FVIII antibodies (for centralized analysis) had to be collected 14 days after the final dose of FVIII administered.

As clinically indicated from baseline until study completion (up to 8 years)

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Investigatori

  • Direttore dello studio: Clinical Trials, Hoffmann-La Roche

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

4 febbraio 2021

Completamento primario (Effettivo)

22 maggio 2023

Completamento dello studio (Stimato)

18 maggio 2030

Date di iscrizione allo studio

Primo inviato

11 giugno 2020

Primo inviato che soddisfa i criteri di controllo qualità

11 giugno 2020

Primo Inserito (Effettivo)

16 giugno 2020

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

1 ottobre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

30 settembre 2026

Ultimo verificato

1 settembre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • MO41787
  • 2020-001733-12 (Numero EudraCT)
  • 2023-505964-13-00 (Identificatore di registro: EU CT Number)
  • 2023 (Sovvenzione/contratto NIH degli Stati Uniti)

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

SÌ

Descrizione del piano IPD

For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

Sì

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .